The ultrastructural basis of renal pathology in monoclonal gammopathies

Journal of Nephrology

Volumn 18, Issue 6, 2005, Pages 659-675

  Santostefano, Marisa ^a   Zanchelli, Fulvia ^a   Zaccaria, Alfonso ^a   Poletti, Giovanni ^a   Fusaroli, Maurizio ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

AL amyloidosis; Cryoglobulinemia; Fanconi syndrome; Immunotactoid glomerulopathy; Light chain; Monoclonal gammopathy; Monoclonal immunoglobulin deposition disease

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; BORTEZOMIB; FIBRINOGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; PROCOLLAGEN C PROTEINASE; TAMM HORSFALL GLYCOPROTEIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID SEQUENCE; AMYLOIDOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; CRYOGLOBULINEMIA; CYTOKINE RELEASE; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; FANCONI RENOTUBULAR SYNDROME; GENETIC COUNSELING; GLOMERULOPATHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY TUBULE DISORDER; MESANGIUM; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; PATHOGENICITY; PLASMA CELL DYSCRASIA; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS; SOMATIC MUTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANIMALS; BIOPSY; GLOMERULAR MESANGIUM; HUMANS; KIDNEY DISEASES; MICROSCOPY, ELECTRON; PARAPROTEINEMIAS;

EID: 30644467493     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Herrera GA. Renal manifestations of plasma cell dyscrasias. An appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol 2000; 4: 174-200.
2. Ronco P, Aucouturier P, Mougenot B. Plasma cell dyscrasia-related glomerulopathies and Fanconi's syndrome: a molecular approach. J Nephrol 2000; 13 (suppl 3): S34-44.
3. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482-92.
4. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001; 10: 543-9.
5. Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC, Simon E, Pontillon F, Lyles M, Bruno J, Hammond TG. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998; 275: F246-54.
6. Bennett EM, Chen CY, Engqvist-Goldstein AE, Drubin DG, Brodsky FM. Clathrin hub expression dissociates the actin-binding protein Hip1R from coated pits and disrupts their alignment with the actin cytoskeleton. Traffic 2001; 2: 851-8.
7. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease. A model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001; 12: 1558-65.
8. Preud'Homme JL, Aucouturier P, Touchard G, Khamlichi AA, Rocca A, Denoroy L, Cogné M. Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations. Int J Immunopharmacol 1994; 16: 425-31.
9. Schiffer M. Molecular anatomy and the pathological expression of antibody light chains. Am J Pathol 1996; 148: 1339-44.
10. Solomon A, Weiss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992; 140: 629-37.
11. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence-Jones proteins. N Engl J Med 1991; 324: 1845-51.
12. Myatt EA, Westholm FA, Weiss DT, Solomon A, Schiffer M, Stevens FJ. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo deposition. Proc Natl Acad Sci U S A 1994; 91: 3034-8.
13. Denoroy L, Déret S, Aucouturier P. Overpresentation of the V kappa IV subgroup in light chain deposition disease. Immumol Lett 1994; 42: 63-6.
14. Comenzo RL, Zhang Y, Martinez C, Osman Y, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001; 98: 714-20.
15. Raffen R, Dieckman LJ, Szpunar M, Wunschl C, Pokkuluri PR, Dave P, Wilkins Stevens P, Cai X, Schiffer M, Stevens FJ. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci 1999; 8: 509-17.
16. Olsen KE, Sletten K, Westermark P. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Biochem Biophys Res Commun 1998; 251: 642-7.
17. Pokkuluri PR, Solomon A, Weiss DT, Stevens FJ, Schiffer M. Tertiary structure of human λ6 light chains. Amyloid 1999; 6: 165-71.
18. Bellotti V, Merlini G. Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant 1996; 11 (suppl 9): S53-62.
19. Schorman N, Murrel JR, Liepnicks JJ, Benson MD. Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc Natl Acad Sci U S A 1995; 92: 9490-4.
20. Bellotti V, Merlini G. Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrol Dial Transplant 1996; 11: 1708-11.
21. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 1994; 91: 5446-50.
22. Bellotti V, Stoppini M, Mangione PP, Fornasieri A, Min L, Merlini G, Ferri G. Structural and functional characterization of three human immunoglobulin kappa light chains with different pathologic implications. Biochim Biophys Acta 1996; 1317: 161-7.
23. Carrel RW, Lomas DA. Conformational disease. Lancet 1997; 350: 134-8.
24. Vendruscolo M, Paci E, Dobson CM, Karplus M. Three key residues form a critical contact network in a protein folding transition state. Nature 2001; 409: 641-5.
25. Stokes MB, Jagirdar J, Burchstin O, Kornacki S, Kumar A, Gallo G. Nodular pulmonary immunoglobulin light chain deposits with coexistent amyloid and non amyloid features in an HIV-infected patient. Mod Pathol 1997; 10: 1059-65.
26. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A 1999; 96: 3590-4.
27. Vidal R, Goni F, Stevens F, Aucouturier P, Kumar A, Frangione B, Ghiso J, Gallo G. Somatic mutations of the L12a gene in VK1 light chain deposition disease. Am J Pathol 1999; 155: 2009-17.
28. Déret S, Chomilier J, Huang DB, Preud'Homme JL, Stevens FJ, Aucouturier P. Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. Protein Eng 1997; 10: 1191-7.
29. Russel WJ, Cardelli J, Harris E, Baier RJ, Herrera GA. Monoclonal light chain-mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest 2001; 81: 689-703.
30. Teng J, Russel WI, Gu X, Cardelli J, Jones ML, Herrera GA. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004; 84: 440-51.
31. Omtvedt LA, Bailey D, Renouf DV, Davies MJ, Paramonov NA, Haavik S, Husby G, Sletten K, Hounsell EF. Glycosylation of immunoglobulin light chains associated with amyloidosis. Amyloid 2000; 7: 227-44.
32. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang Z-Q, Sanders PW. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-β. Am J Pathol 1995; 147: 375-85.
33. Zhu L, Herrera GA, White CR, Sanders PW. Immunoglobulin light chain alters mesangial cell calcium homeostasis. Am J Physiol 1997; 272: F319-24.
34. Herrera GA, Russel WJ, Turbat-Herrera E, Tagouri YM, Sanders PW, Picken MM, Dempsey S. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol 1999; 23: 107-26.
35. Turbat-Herrera EA, Isaac J, Sanders PW, Truong LD, Herrera GA. Integrated expression of glomerular extracellular matrix proteins and β1 integrins in monoclonal light chain-related diseases. Mod Pathol 1997; 10: 485-95.
36. Richardson PG, Barlogie BB, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkien DP, Anderson KC. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
37. Border WA, Noble NA, Yamamoto T, HarperJR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of TGFβ protects against scaring in experimental kidney disease. Nature 1992; 360: 361-4.
38. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 8: 45-59.
39. Herrera GA, Russel WJ, Cardelli J. Phenotypic transformation of mesangial cells precedes and is required for AL-amyloidogenesis. In Bely M, Apathy D, (Eds). Proceeding of the IX International Symposium on Amyloidosis. Budapest: 2001; 267-72.
40. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
41. Isaac J, Kerby JD, Russel WJ, Dempsey SC, Sanders PW, Herrera GA. In vitro modulation of AL-Amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid 1998; 5: 238-46.
42. Dalomi D, Weber D, Alexanian R. Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol 1995; 50: 296-8.
43. Buxbaum JN. Abnormal immunoglobulin synthesis in monoclonal immunoglobulin light chain and light and heavy chain deposition disease. Amyloid 2001; 8: 84-93.
44. Tubbs RR, Berkley V, Valenzuela R, Mc Mahon JT, Gephardt GN, Fishleder AJ, Nally JV, Pohl MA, Bukowski RM, Lichtin AE. Pseudo-heavy chain (IgG4) deposition disease. Mod Pathol 1992; 5: 185-90.
45. Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D'Agati VD. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis 1999; 33: 954-62.
46. Nasr SH, Lobritto SJ, Lauring BP, Arend LJ, D'Agati VD, Markowitz GS. A rare complication of monoclonal gammopathy. Am J Kidney Dis 2002; 40: 867-71.
47. Cheng I, Ho S, Chan D, Ng W, Chan K. Crescentic nodular glomerulosclerosis secondary to truncated immunoglobulin a deposition. Am J Kidney Dis 1996; 28: 283-8.
48. Liapis H, Papadakis I, Nakoponjon L. Nodular glomerulosclerosis secondary to μ heavy chain deposits. Hum Pathol 2000; 31: 122-5.
49. Soma J, Sato K, Sakuma T, Saito H, Sato H, Sato T, Abbas A, Aucouturier P. Immunoglobulin γ3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis 2004; 43: 10-6 E2.
50. Hendershot L, Bole D, Kearney JF. Assembly and secretion of heavy chains that do not associate post translationally with immunoglobulin heavy chain-binding protein. J Cell Biol 1987; 104: 761-7.
51. Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. γ-heavy chain disease. Review of 23 cases. Medicine 2003; 82: 236-50.
52. Mai HL, Sheikh-Hamad D, Herrera GA, Gu X, Truong LD. Immunoglobulin heavy chain can be amyloidogenic. Am J Surg Pathol 2003; 27: 541-5.
53. De Fronzo RA, Cooke CR, Wright JR, Humphrey RL. Renal function in patients with multiple myeloma. Medicine 1978; 57: 151-66.
54. Maldonado JE, Velosa JA, Kyle RA, Wagoner RD, Holley KE, Salassa RM. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med 1975; 58: 354-64.
55. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, Dion JJ, Makdassi R, Meeus F, Pourrat J, Touchard G, Vanhille P, Zaoui P, Aucouturier P, Ronco PM. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine 2000; 79: 135-54.
56. Rochman J, Lichting C, Osterweill D, Tatarsky I, Eidelman S. Adult Fanconi's syndrome with renal tubular acidosis in association with renal amyloidosis: occurrence in a patient with chronic lymphocytic leukemia. Arch Intern Med 1980; 140: 1361-3.
57. Rikitake O, Sakemi T, Yoshikawa Y, Nagano Y, Watanabe T. Adult Fanconi syndrome in primary amyloidosis with lambda light-chain proteinuria. Jpn J Med 1989; 28: 523-6.
58. Deret S, Denoroy L, Lamarine M, Vidal R, Mougenot B, Frangione B, Stevens FJ, Ronco PM, Aucouturier P. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng 1999; 12: 363-9.
59. Guan S, El-Dahr S, Dipp S, Batuman V. Inibition of Na-K-AT-Pase activity and gene expression by a myeloma light chain in proximal tubule cells. J Investig Med 1999; 47: 496-501.
60. Eiam-Ong S, Sphon M, Kurtzman NA, Sabatini S. Insight into the biochemical mechanisms of maleic acid-induced Fanconi syndrome. Kidney Int 1995; 48: 1542-8.
61. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. Review article. N Engl J Med 1998; 339: 1448-56.
62. Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FW, Thakker RV, Unwin RJ, Wrong O. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 2001; 60: 1885-92.
63. Iványi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence-Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990; 114: 986-7.
64. Huang Z-Q, Sanders PW. Biochemical interaction of Tamm-Horsfall glycoprotein with Ig light chains. Lab Invest 1995; 73: 810-7.
65. Kumar S, Muchmore A. Tamm-Horsfall protein-uromodulin. Kidney Int 1990; 37: 1395-401.
66. Rindler MJ, Naik SS, Li N, Hoops TC, Peraldi MN. Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J Biol Chem 1990; 265: 20784-9.
67. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001; 158: 1859-66.
68. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence-Jones protein. J Clin Invest 1992; 89: 630-9.
69. Huang ZQ, Kirk KA, Connelly KG, Sanders PW. Bence-Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Invest 1993; 92: 2975-83.
70. Williams J, Marshall RD. Structural analysis of the carbohydrate moieties of human Tamm-Horsfall glycoprotein. Carbohydr Res 1984; 134: 141-55.
71. Huang ZQ, Sanders P. Biochemical interaction between Tam-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 1995; 73: 810-7.
72. Myatt EA, Westholm FA, Weiss DT, Solomon A, Schiffer M, Stevens FJ. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci U S A 1994; 91: 3034-8.
73. Iggo N, Winearls CG, Davies DR. The development of cast nephropathy in multiple myeloma. Q J Med 1997; 90: 653-6.
74. Cleave AJ, Kent PW, Peacocke AR. The binding of hydrogen and calcium ions by Tamm-Horsfall glycoprotein. Biochim Biophys Acta 1972; 285: 208-23.
75. Handford PA, Mayhew M, Baron M, Winship PR, Campbell ID, Brownlee GG. Key residues involved in calcium-binding motifs in EGF-like domains. Nature 1991; 351: 164-7.
76. Karras A, Noël LH, Droz D, Delansorne, Saint-André JP, Aucouturier P, Alyanakian MA, Grünfeld JP, Lesavre P. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3k cryoglobulin. Am J Kidney Dis 2002; 40: 1091-6.
77. Bridoux F, Provôt F, Ayache RA, Gonjon JM, Touchard G. Atteinte rénal an cours des cryoglobulinémies de type I. Presse Med 2003; 32: 570-3.
78. Provot F, Bridoux F, Vanhille P. Spectrum of glomerular disease in type I cryoglobulinemia. J Am Soc Nephrol 2000; 11: 95A.
79. Lemoine R, Berney T, Shibata T. Induction of "wire-loop" lesions by murine monoclonal IgG3 cryoglobulins. Kidney Int 1992; 41: 65-72.
80. Panka DJ, Salant DJ, Jacobson BA, Minto AW, Marshak-Rothstein A. The effect of VH residues 6 and 23 on IgG3 cryoprecipitation and glomerular deposition. Eur J Immunol 1995; 25: 279-84.
81. Rengers J-U, Touchard G, Decourt C, Deret S, Michel H, Cogné M. Heavy and light chain primary structures control IgG3 nephritogenicity in an experimental model for cryocrystalglobulinemia. Blood 2000; 95: 3467-72.
82. Kuroki A, Kuroda Y, Kikuchi S, Lajaunias F, Fulpius T, Pastore Y, Fossati-Jimack L, Reininger L, Toda T, Nakata M, Kojima N, Mizuochi T, Izui S. Level of galactosylation determines cryoglobulin activity of murine IgG3 monoclonal rheumatoid factor. Blood 2002; 99: 2922-8.
83. Panka DJ. Glycosylation is influential in murine IgG3 self-association. Mol Immunol 1997; 34: 593-8.
84. Mizuochi T, Pastore Y, Shikata K, Kuroki A, Kikuchi S, Fulpius T, Nakata M, Fossati-Jimack L, Reininger L, Matsushita M, Fujita T, Izui S. Role of galactosylation in the renal pathogenicity of murine immunoglobulin G3 monoclonal cryoglobulins. Blood 2001; 97: 3537-43.
85. Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003; 63: 1450-61.
86. Brady HR. Fibrillary glomerulopathy. Kidney Int 1998; 53: 1421-9.
87. Bridoux F, Hugue V, Coldefy O, Goujon JM, Bauwens M, Sechet A, Preud'Homme JL, Touchard G. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002; 62: 1764-75.
88. Touchard G, Bauwens M, Goujon JM. Glomerulonephritis with organized micrombular monoclonal immunoglobulin deposits. Adv Nephrol Necker Hosp 1994; 23: 149-75.
89. Van Ginneken EE, Assmann KJ, Koolen MI. Fibrillary-immunotactoid glomerulopathy with renal deposits of IgAλ: a rare cause of glomerulonephritis. Clin Nephrol 1999; 52: 383-9.
90. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999; 56: 355-77.
91. Nasr SH, Markowitz GS, Stokes MB. Proliferative glomerulonephritis with monoclonal IgG deposits. A distinct entity mimicking immunocomplex glomerulonephritis. Kidney Int 2004; 65: 85-96.
92. Cutillas P, Norden A, Cramer R, Burlingame A, Unwin R. Urinary proteonomics of renal Fanconi Syndrome. Contrib Nephrol 2004; 141: 155-69.